5 Best Genomic Stocks to Buy Now

Page 1 of 5

In this article, we will take a look at the 5 best genomic stocks to buy now. For a detailed analysis of the genomics industry and a more comprehensive list of stocks, go directly to the 11 Best Genomic Stocks to Buy Now.

5. Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Number of Hedge Fund Holders: 41

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is the fifth stock on our list of the 10 best genomic stocks to buy now. The biotech company was founded in 2014 to create biopharmaceuticals using the CRISPR gene-editing system. In 2015, Intellia Therapeutics, Inc. (NASDAQ:NTLA) partnered with Novartis AG (NYSE:NVS) to utilize CRISPR to create treatments for beta thalassemia and sickle cell disease. 

41 out of 873 hedge funds tracked by Insider Monkey held stakes amounting to $2.28 billion in Intellia Therapeutics, Inc. (NASDAQ:NTLA) at the end of the second quarter of 2021. This is compared to 29 hedge funds in the previous quarter with stakes valued at $1.13 billion. 

On October 5, Guggenheim analyst Debjit Chattopadhyay initiated coverage of Intellia Therapeutics, Inc. (NASDAQ:NTLA) with a Buy rating and raised the price target to $170. 

The clinical trial application by  Intellia Therapeutics, Inc. (NASDAQ:NTLA) was approved by New Zealand Medicines and Medical Devices Safety Authority to initiate a study for treating adults with hereditary angioedema. This clinical trial would determine the correct dosage of NTLA-2002 for future studies. 

Catherine Wood’s ARK Investment Management is the leading stakeholder in  Intellia Therapeutics, Inc. (NASDAQ:NTLA), with 7.68 million shares amounting to $1.24 billion. 

In their Q2 2021 investor letter, Carillon Tower Advisers discussed their stance on  Intellia Therapeutics, Inc. (NASDAQ:NTLA). Here is what they said: 

“Intellia Therapeutics is a clinical-stage genome editing company focused on the development of proprietary, potentially curative therapeutics. The company’s stock soared after announcing positive interim data from an ongoing phase 1 clinical study of its in vivo gene editing candidate, which is being developed as a single-dose treatment for hereditary transthyretin (ATTR) amyloidosis. This specific form of therapy would be the first of its kind resulting in the precision editing of a gene in a target tissue in the human body.”

Page 1 of 5